Alto Neuroscience (ANRO) Accounts Payables (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Accounts Payables data on file, last reported at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 143.42% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (up 143.42% YoY), and the FY2025 full-year result was $1.9 million, up 18.94% from the prior year.
• Accounts Payables rose to $3.4 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.4 million in Q1 2026 to a low of $1.1 million in Q4 2023.
• A 4-year average of $2.0 million and a median of $1.9 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables slumped 42.62% in 2025 and soared 143.42% in 2026, its largest moves.
• Tracing ANRO's Accounts Payables over 4 years: stood at $1.1 million in 2023, then jumped by 47.02% to $1.6 million in 2024, then increased by 18.94% to $1.9 million in 2025, then surged by 79.39% to $3.4 million in 2026.
• Business Quant data shows ANRO's Accounts Payables at $3.4 million in Q1 2026, $1.9 million in Q4 2025, and $2.1 million in Q3 2025.